Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Ready when it matters most

NovoSeven® RT is there for your patients when bleeds happen.

Ready when it matters most

NovoSeven® RT is there for your patients when bleeds happen.

“There’s one patient I’ll never forget. When it was time to consider a joint replacement surgery, we knew where to turn for effective treatment.“1

Actor portrayal

“There’s one patient I’ll never forget. When it was time to consider a joint replacement surgery, we knew where to turn for effective treatment.“1

Actor portrayal


The experience continues

NovoSeven® RT has 30+ years of research and long-term clinical experience; 1,106 patients and 5,305 bleeds treated in registrational studies and ~400 successful surgeries and procedures.1-25,a-c

Blood droplet next to an x icon

Effective control of the mildest to most life-threatening bleeds

Proven effective for bleed resolution and surgery across 4 indications.1. NovoSeven® RT is the only rFVIIa indicated for CHwI patients of all ages.1

Vials icon

Clinical experience with Hemlibra®

NovoSeven® RT was the only recombinant factor used for breakthrough bleeds in patients with inhibitors in the Hemlibra® pivotal clinical trials.26,d

MASAC recommends rFVIIa to treat acute bleeds in patients with congenital hemophilia A with inhibitors taking emicizumab prophylaxis.27

Clock icon

Able to quickly treat bleeds when they occur

Rapid administration and infusion, leading to rapid activity.1,28 A median of 2 doses helped control joint bleeds in as little as 5 hours in CHwI patients.29,e

Backpack icon

Portability to fit into your patients’ lives

Room temperature stable for rapid access to treatment. Everything patients need to reconstitute is in one small box.1,f

Mixing icon

#1 prescribed rFVIIa in hospitals30

NovoSeven® RT is the only rFVIIa approved for surgery and for use in patients of all ages.1

Shield with checkmark icon

A well-established safety profile

A low rate of thrombotic events based on clinical trials and registries.1,g

  • 0.2% of bleeding episodes in patients with CHwI 
  • 4% in patients with AH 
  • <0.2% in patients with GT
  • 0.8% in patients with CFVIId31,g

And NovoSeven® RT is not made from human serum or human proteins.1,30

a1988: compassionate use initiated in the United States; 1999: FDA approval received for CHwI.30

bIncludes bleeding episodes, major and minor surgical procedures, traumatic injuries, and prophylaxis regimens.

cSuccess was defined differently in each study.

dThe analysis included bleeding episodes in the HAVEN1, HAVEN2, and HAVEN4 clinical trials for which patients with CHAwI on emicizumab prophylaxis (at the labeled dose) used rFVIIa. Initial individual dosing with rFVIIa, dosing intervals, and cumulative dosing were evaluated. All AEs reported in each of the 3 trials, including available narratives, were assessed. The cut-off dates for data presented were for HAVEN1 (primary analysis) September 2017; HAVEN2 (interim analysis) October 2017; and HAVEN4 (primary analysis) December 2017.26

eData from a randomized, double-blind, parallel-group, multicenter study of patients with hemophilia A or B with and without an inhibitor. Patients were given NovoSeven® RT at dosing intervals of 2 to 3 hours. Efficacy reflects the number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent” if a patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of the bleed (or arrest of bleeding) in 8 hours or less. An “effective” response was measured by any of these 3 events occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated detectable relief of pain/tenderness or decrease in bleeding.29

fPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36-77˚F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.

gData based on postmarketing retrospective safety assessment of clinical trials and registries.31


NovoSeven® RT effectively controls joint bleeds in CHwI—fast.29

Hemostasis was  achieved with a median of 2 doses.29,h

Clock displaying 2 hours

Quick readministration

NovoSeven® RT can be readministered as quickly as every 2 hours compared with 6 to 12 hours for FEIBA®1,32

Medication icon

Median 2 doses

A median of 2 doses helped control joint bleeds in as little as 5 hours29,h

Person standing next to an up arrow

Maximum activity

NovoSeven® RT achieved maximum activity within 5-10 minutes of infusion28,i,j

Explore real-world data

hData from a randomized, double-blind, parallel-group, multicenter study of patients with hemophilia A or B with and without an inhibitor. Patients were given NovoSeven® RT at dosing intervals of 2 to 3 hours. Efficacy reflects the number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent” if a patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of the bleed (or arrest of bleeding) in 8 hours or less. An “effective” response was measured by any of these 3 events occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated detectable relief of pain/tenderness or decrease in bleeding.29

iData from a randomized, double-blind trial of healthy subjects (N=22) who received 1 intravenous bolus injection each of NovoSeven® RT and NovoSeven®. Both bolus injections were 90 mcg/kg and occurred 2 to 3 weeks apart at consecutive visits. While the comparison is not shown for FVIIa, activity for NovoSeven® RT was the bioequivalent range of that for NovoSeven® during this period.28

 jFVIIa activity IU/mL.28

NovoSeven® RT helps a broad range of patients

with the treatment of bleeding episodes and perioperative management1

Product comparison chart

Indications

NovoSeven® RT1,k

FEIBA®32,l

OBIZUR®34,m

SEVENFACT®35,n,o

Congenital hemophilia A with inhibitors

Red triangle and blue circle
Red triangle and blue circle
Red triangle

Congenital hemophilia B with inhibitors

Red triangle and blue circle
Red triangle and blue circle
Red triangle

Acquired hemophiliap

Red triangle and blue circle
Red triangle

Congenital factor VII deficiency

Red triangle and blue circle

Glanzmann's thrombasthenia

with refractoriness to platelet transfusions, with or without antibodies to platelets

Red triangle and blue circle
Red triangle

= bleed treatment;

Blue circle

= perioperative management




Disclaimer: This chart is not intended to compare efficacy or safety.

kNovoSeven® RT is a recombinant FVIIa.

lFEIBA is an activated prothrombin complex concentrate (aPCC) and is also indicated for prophylaxis in CHAwI and CHBwI patients.

mOBIZUR is a porcine sequence recombinant FVIII.

nSEVENFACT is a recombinant FVIIa.

oSEVENFACT is only indicated for adults and adolescents (12 years and older).

pAdults with acquired hemophilia.


Learn more about how NovoSeven® RT helps your patients with:

Congenital Hemophilia A or B With Inhibitors

Acquired Hemophilia
 

Congenital Factor VII Deficiency
 

Glanzmann’s Thrombasthenia With Refractoriness to Platelets
 

Man using MixPro® to reconstitute NovoSeven® RT

Patients can use MixPro® to reconstitute NovoSeven® RT.

See the 3 steps
Illustration of NovoSeven® RT mechanism of action

NovoSeven® RT mechanism of action.

How it works
Rare bleeding disorders patient education materials

Help your patients learn about rare bleeding disorders.

View education materials

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References

1. NovoSeven RT. Package insert. Novo Nordisk Inc; 2020.

2. Data on file as of 2010. Novo Nordisk Inc; Plainsboro, NJ.

3. Shapiro AD, Neufeld EJ, Blanchette VS, et al. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital hemophilia with inhibitors: overall dose exposure and intervals following >240-mcg/kg doses across trial, registry, and diary studies. Poster presented at: 53rd Annual Meeting and Exposition of the American Society of Hematology; December 10-13, 2011; San Diego, California.

4. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778. 

5. Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11:100-106. 

6. Ingerslev J, Friedman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis. 1996;26:118-123. 

7. Rodriguez-Merchan EC, Wiedel JD, Wallny T, et al. Elective orthopedic surgery for hemophilia patients with inhibitors: new opportunities. Semin Hematol. 2004;41(1):109-116.

8. Giangrande PLF, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated): NovoSeven®] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009;15:501-508. 

9. Takedani H, Kawahara H, Kajiwara M. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. Haemophilia. 2010;16:290-295. 

10. Boadas A, Fernandez-Palazzi F, De Bosch NB, et al. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela. Haemophilia. 2011;17:422-427. 

11. Polyanskaya T, Zorenko V, Karpow E, et al. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors. Haemophilia. 2012;18:997-1002. 

12. Takedani H, Shima M, Horikoshi Y, et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia. 2015;21:374-379. 

13. Balkan C, Karapinar D, Aydogdu S, et al. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia. 2010;16:902-909. 

14. Salaj P, Gurlich R, Svorcova V, et al. Prophylactic preparation and surgical extirpation of a very large abdominal blood cyst in a severe haemophilia A patient with inhibitors managed by rFVIIa. Haemophilia. 2009;15:380-382. 

15. Valentino LA, Cooper DL, Goldstein B. Surgical Experience with rFVIIa (NovoSeven®) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia. 2011;17:579-589. 

16. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, et al. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia. 2010;16:84-88. 

17. Caviglia H, Candela M, Galatro G, et al. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature. Haemophilia. 2011;17:910-919.

18. Banov L, Pavanello M, Piattelli G, et al. Successful urgent neurosurgery management with rFVIIa mega doses in a child with haemophilia A and high titre inhibitor. Blood Coagul Fibrinolysis. 2014;25:518-521. 

19. de Souza DG, Waldron PE, Peeler BB, et al. The use of activated factor VII for ventricular septal defect closure in a pediatric patient with hemophilia A and a high titer of inhibitor. J Cardiothorac Vasc Anaesth. 2009;23(5):679-681. 

20. Aouba A, Dezamis E, Sermet A, et al. Uncomplicated neurosurgical resection of a malignant glioneuronal tumour under haemostatic cover of rFVIIa in a severe haemophilia patient with a high-titre inhibitor: a case report and literature review of rFVIIa use in major surgeries. Haemophilia. 2010;16:54-60. 

21. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in highresponder haemophilia patients. Haemophilia. 2004;10(2):46-49. 

22. Watts, RG. Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity. Am J Haematol. 2005;79:58-60. 

23. Rajic N, Savic A, Popovic S, et al. Successful control of bleeding during supracondylar amputation caused by severe compartment syndrome in patient with haemophilia A and high titre of inhibitor. Haemophilia. 2009;15:601-602. 

24. Mehta S, Nelson CL, Konkle BA, et al. Total knee arthroplasty using recombinant factor VII in hemophilia-A patients with inhibitors. J Bone Joint Surg Am. 2004;86-A(2):2519-2521. 

25. Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Thromb Haemost. 2007;98(4):726-732.

26. Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470-1477.

27. MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed June 20, 2023. https://www.hemophilia.org/sites/default/files/document/files/268_emicizumab.pdf

28. Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5):527-532.

29. Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.

30. Data on file as of 2021. Novo Nordisk Inc; Plainsboro, NJ.

31. Rajpurkar M, Croteau SE, Boggio L, et al. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019;10:335-340.

32. FEIBA. Package insert. Baxter Healthcare Corporation; 2023.

33. Hedner U. History of rFVIIa therapy. Thromb Res. 2010;125:S4-S6.

34. Obizur. Package insert. Baxter Healthcare Corporation; 2023.

35. SEVENFACT. Package Insert. HEMA Biologics; 2022.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
MixPro® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

 

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved.  US23NSVN00011  August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials